Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Conditions
Interventions
AK117
Placebo
+1 more
Locations
15
United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda)
Bethesda, Maryland, United States
Maryland Oncology-Columbia
Columbia, Maryland, United States
Start Date
February 7, 2024
Primary Completion Date
January 1, 2026
Completion Date
June 1, 2026
Last Updated
February 11, 2025
Lead Sponsor
Akeso
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions